Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...

Jan 30 (Reuters) - Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong ...

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...

Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...

Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Cardinal Health has reported second quarter revenue for its “other” businesses, which includes at-Home Solutions, increased 13% to $1.3 billion.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.